Ventricular Assist Devices (VAD)

This channel includes news and new technology innovations for ventricular assist devices (VAD). VADs are a type of mechanical hemodynamic support device that helps increase blood flow in people who have ventricles that are not work properly due to heart failure, cardiogenic shock, cardiomyopathy or myocardial infarction. Most often these devices support the left ventricle, so they are often referred to as left ventricular assist devices (LVAD). VADS come in two types, surgically implanted, usually as a bridge to heart transplant, and percutanenous catheter-based pumps used for temporary hemodynamic support. Examples of temporary percutaneous pumps include the Impella and TandemHeart devices.

 

Medtronic announced in June it was stopping the sale and distribution of the Medtronic Heartware HVAD left ventricular assist device (LVAD). Abbott announced the same day it has the capacity to meet increased demand for LVADs as Medtronic leaves the market.

Medtronic announced in June it was stopping the sale and distribution of the Medtronic Heartware HVAD left ventricular assist device (LVAD). Abbott announced the same day it has the capacity to meet increased demand for LVADs as Medtronic leaves the market.

Feature | Ventricular Assist Devices (VAD) | July 08, 2021 | By Dave Fornell, Editor
Medtronic announced in June it was stopping the sale and distribution of the Medtronic Heartware HVAD left ventricular...
The Carmat system, an experimental artificial heart includes an autoregulation control mechanism, or Auto-Mode, that can adjust to the changing needs of patients treated for end-stage heart failure. Outcomes in the first series of patients managed with the new heart replacement pump in Auto-Mode are presented in the journal of the American Society for Artificial Internal Organs (ASAIO). 

The Carmat artificial heart technology.

News | Artificial Heart | June 23, 2021
June 18, 2021 – An experimental artificial heart includes an autoregulation control mechanism, or Auto-Mode, that can...
FDA Clears Pradaxa as First Oral Anticoagulant for Children. Dabigatran, has been cleared by the FDA
News | Antiplatelet and Anticoagulation Therapies | June 21, 2021
June 21, 2021 — The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim's dabigatran etexilate (...
Videos | Ventricular Assist Devices (VAD) | March 22, 2021
Surgeons at Penn State Heart and Vascular Institute were the second group in the nation to implant a newly-designed...
The Teleflex Manta large-bore vascular closure device can seal holes between 12 and 25 French.

The Teleflex Manta large-bore vascular closure device can seal holes between 12 and 25 French. 

Feature | Hemostasis Management | March 09, 2021 | Dave Fornell, Editor
While many cardiac and vascular procedures have largely moved to minimally invasive techniques, the size of these...
LVAD patient Richard Huggins with the external control and power unit for his new EvaHeart2 left ventricular assist device at Penn State Health's Hershey Medical Center. 

LVAD patient Richard Huggins with the external control and power unit for his new EvaHeart2 left ventricular assist device at Penn State Health's Hershey Medical Center. 

News | Heart Failure | March 02, 2021
March 2, 2021 — Penn State Health Milton S. Hershey Medical Center became the second hospital in the nation to implant...
Medtronic Recalls HVAD Pump Implant Kits After 2 Deaths and 19 Serious Injuries
News | Ventricular Assist Devices (VAD) | March 01, 2021
March 1, 2021 — Medtronic is recalling the HeartWare Ventricular Assist Device (HVAD) Pump Implant Kit because the left...
The FineHeart Transcutaneous Energy Transfer (TET) System for the ICOMS cardiac assist device. 1. The ICOMS heart pump. 2. The implanted TET transfer pad. 3. The external energy transfer pad.

The FineHeart Transcutaneous Energy Transfer (TET) System for the ICOMS cardiac assist device. 1. The ICOMS heart pump. 2. The implanted TET transfer pad. 3. The external energy transfer pad.

News | Heart Failure | January 13, 2021
January 13, 2021 — FineHeart, a preclinical-stage medical device company developing a novel left ventricular assist...
HeartMate 3 heart pump is now approved for use for pediatric patients battling advanced heart failure offering a new treatment option for this underserved population
News | Heart Failure | December 21, 2020
December 21, 2020 — U.S. Food and Drug Administration (FDA) approved updated labeling December 17 for Abbott's...
CMS coverage changes effective as of Dec. 2, 2020 will open up the use of LVADs to more Medicare patients, including use of the HeartWare and HeartMate ventricular assist devices.

CMS coverage changes effective as of Dec. 2, 2020 will open up the use of LVADs to more Medicare patients, including use of the HeartWare and HeartMate ventricular assist devices.

News | Heart Failure | December 02, 2020
December 2, 2020 — The Centers for Medicare and Medicaid Services (CMS) finalized updates to Medicare coverage policies...
Videos | Hemodynamic Support Devices | October 20, 2020
Chuck Simonton, M.D., chief medical officer at Abiomed, discusses some of the new technologies and clinical trials the...
The Abiomed Impella was highlighted in several sessions at the 2020 TCT Connect conference. #TCT #TCT2020 #TCTconnect
News | Hemodynamic Support Devices | October 16, 2020
October 16, 2020 — The Restore EF Study demonstrates the use of contemporary best practices, including attempting a...
The Medtronic Heartware and Abbott Heartmate 3 LVADs and others currently cleared by the FDA might be easier to use in Medicare advanced heart failure patients under new guidelines proposed by CMS. Photo by Dave Fornell

The Medtronic Heartware and Abbott Heartmate 3 LVADs and others currently cleared by the FDA might be easier to use in Medicare advanced heart failure patients under new guidelines proposed by CMS. Photo by Dave Fornell

Feature | Heart Failure | August 21, 2020 | Dave Fornell, Editor
August 21, 2020 — The U.S. Centers for Medicare and Medicaid Services (CMS) proposed updates to coverage policies for...
Abiomed Impella is now authorized to treat critical ICU COVID-19 patients on ECMO who develop pulmonary edema or need cardiac decompensation from myocarditis. #COVID19 #SARScov2 #Impella

Abiomed Impella is now authorized to treat critical ICU COVID-19 patients on ECMO who develop pulmonary edema or need cardiac decompensation from myocarditis.

Feature | Coronavirus (COVID-19) | August 05, 2020 | Dave Fornell, Editor
August 5, 2020 — The U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) this week for...
Abiomed announced the U.S. Food and Drug Administration (FDA) has approved the company's investigational device exemption (IDE) application to start an early feasibility study with a first-in-human trial of the 9 French (Fr) Impella ECP heart pump. Impella ECP, which stands for "expandable cardiac power," will be studied in high-risk percutaneous coronary intervention (PCI) patients.
News | Hemodynamic Support Devices | June 05, 2020
June 5, 2020 — Abiomed announced the U.S. Food and Drug Administration (FDA) has approved the company's investigational...